Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of all pancreatic
cancers and is the most fatal of all cancers. The treatment response from combination …

Pancreatic cancer is still a clinical challenge due to its predominantly late diagnosis and the
chemoresistance to cytotoxic and target drugs. One of the major complications of pancreatic …

Pancreatic cancer is still a major clinical challenge. Recent efforts to improve survival in
locally advanced and metastatic disease have focused on combining cytotoxic drugs with …

Background Venous thrombo-embolic events (VTE) frequently occur in patients with
pancreatic ductal adenocarcinoma (PDAC) and contribute to high morbidity and mortality …

Pancreatic cancer (PC) is a devastating malignancy with fewer than 10% of patients being
alive at 5 years after diagnosis. Venous thromboembolism (VTE) occurs in approximatively …

Venous thromboembolism (VTE) frequently occurs in patients with cancer, and particularly
those with pancreatic ductal adenocarcinoma (PDAC). Therapeutic anticoagulation with …

Background/Aim: A well-known complication of pancreatic adenocarcinoma (PDAC) is
venous thromboembolism (VTE). The Khorana score is used as a tool to help determine the …

Pancreatic cancer (PC) is a devastating malignancy with an overall 5-year survival of 8% for
all stages combined. Most of the PC patients diagnosed have an advanced disease (40%) …

Introduction. Cancer-associated thrombosis is a significant prognostic marker in pancreatic
neoplasia, with a venous thromboembolism incidence of 17-34%. This study focuses on …

Introduction Pancreatic cancer is associated with a high risk of venous thromboembolism
(VTE). However, comprehensive data on incidence, timing and relevant determinants of VTE …